TY - JOUR T1 - Cytomegalovirus: an unrecognised potential contributor to cystic fibrosis disease progression? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01727-2018 VL - 53 IS - 4 SP - 1801727 AU - Michael D. Parkins AU - Kathleen J. Ramos AU - Christopher H. Goss AU - Ranjani Somayaji Y1 - 2019/04/01 UR - http://erj.ersjournals.com/content/53/4/1801727.abstract N2 - Cytomegalovirus (CMV) is a betaherpesvirus, the impacts of which are well known to clinicians providing post-transplant cystic fibrosis care. Lung transplant recipients have the highest risk of any solid-organ transplant for CMV reactivation and ganciclovir resistance [1, 2]. Furthermore, CMV reactivation increases the risk of chronic lung allograft dysfunction. However, even in general populations, CMV seropositivity is associated with adverse outcomes including cognitive impairment, frailty, heart disease and all-cause mortality [3–5]. How CMV may contribute to disease is not evident but many streams of evidence suggest CMV replication in inflamed sites contributes to exaggerated inflammation and tissue injury [6].Of cystic fibrosis (CF) patients referred for lung transplant consideration, those who are cytomegalovirus (CMV) IgG+ at referral are 8 years younger than seronegatives, suggesting CMV may have a pathogenic role in CF lung disease http://ow.ly/iSQf30nAxxl ER -